PSA筛查前列腺癌的系统综述与荟萃分析
全证据体显示筛查可能对全因死亡率无影响(IRR 0.99, 95%CI 0.98-1.01),对前列腺癌特异性死亡率可能无影响(IRR 0.96, 95%CI 0.85-1.08)。低偏倚风险研究敏感性分析显示筛查可能对前列腺癌特异性死亡率有小幅影响(IRR 0.79, 95%CI 0.69-0.91),相当于每1000名男性筛查10年减少1例前列腺癌死亡。
要点
- PSA筛查对全因死亡率可能无影响(IRR 0.99, 95%CI 0.98-1.01)。
- 低偏倚风险研究显示筛查可能小幅降低前列腺癌死亡率(IRR 0.79, 95%CI 0.69-0.91)。
- 每1000名男性筛查10年约减少1例前列腺癌死亡,但需权衡活检和治疗并发症。
核心结论
- PSA筛查至多小幅降低10年前列腺癌特异性死亡率,但对全因死亡率无影响。
- 临床医生和患者需权衡筛查的潜在获益与短期和长期危害,包括活检和治疗并发症及过度诊断和过度治疗风险。
研究设计与样本
- 系统综述与荟萃分析,检索Cochrane Central Register of Controlled Trials、Web of Science、Embase、Scopus、OpenGrey、LILACS和Medline等数据库至2018年4月。
- 至少两名评价者筛选研究、提取数据并评估质量,采用随机效应模型计算合并发病率比(IRR),并进行预设亚组分析和基于偏倚风险的敏感性分析,使用GRADE评估证据质量。
主要发现
- 全证据体:筛查对全因死亡率可能无影响(IRR 0.99, 95%CI 0.98-1.01;中等确定性),对前列腺癌特异性死亡率可能无影响(IRR 0.96, 95%CI 0.85-1.08;低确定性)。
- 低偏倚风险研究(n=1)敏感性分析:筛查对全因死亡率似乎无影响(IRR 1.0, 95%CI 0.98-1.02;中等确定性),但对前列腺癌特异性死亡率可能有小幅影响(IRR 0.79, 95%CI 0.69-0.91;中等确定性),相当于每1000名男性筛查10年减少1例前列腺癌死亡。
- 基于建模估计,每1000名男性筛查,约分别有1、3、25名男性因脓毒症住院、需要尿失禁垫、报告勃起功能障碍。
关键数值与推荐
- 纳入标准:比较PSA筛查与常规护理的随机对照试验,男性无前列腺癌诊断。
- 主要结局:全因死亡率和前列腺癌特异性死亡率,采用随机效应模型合并IRR。
- 证据质量采用GRADE方法评估。
临床怎么用
- 临床医生与患者讨论PSA筛查时,应权衡小幅降低前列腺癌死亡率的潜在获益与活检并发症、治疗相关并发症(如脓毒症、尿失禁、勃起功能障碍)及过度诊断和过度治疗的风险。
局限性
- 纳入试验在筛查频率和间隔、活检PSA阈值及偏倚风险方面存在差异。
- 关于活检和治疗相关并发症的直接比较数据有限。
- 部分结局证据确定性为低或中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostate cancer. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic search of Cochrane Central Register of Controlled Trials, Web of Science, Embase, Scopus, OpenGrey, LILACS, and Medline, and search of scientific meeting abstracts and trial registers to April 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing PSA screening with usual care in men without a diagnosis of prostate cancer. DATA EXTRACTION: At least two reviewers screened studies, extracted data, and assessed the quality of eligible studies. A parallel guideline committee (BMJ Rapid Recommendation) provided input on the design and interpretation of the systematic review, including selection of outcomes important to patients. We used a random effects model to obtain pooled incidence rate ratios (IRR) and, when feasible, conducted subgroup analyses (defined a priori) based on age, frequency of screening, family history, ethnicity, and socioeconomic level, as well as a sensitivity analysis based on the risk of bias. The quality of the evidence was assessed with the GRADE approach. RESULTS: Five randomised controlled trials, enrolling 721 718 men, were included. Studies varied with respect to screening frequency and intervals, PSA thresholds for biopsy, and risk of bias. When considering the whole body of evidence, screening probably has no effect on all-cause mortality (IRR 0.99, 95% CI 0.98 to 1.01; moderate certainty) and may have no effect on prostate-specific mortality (IRR 0.96, 0.85 to 1.08; low certainty). Sensitivity analysis of studies at lower risk of bias (n=1) also demonstrates that screening seems to have no effect on all-cause mortality (IRR 1.0, 0.98 to 1.02; moderate certainty) but may have a small effect on prostate-specific mortality (IRR 0.79, 0.69 to 0.91; moderate certainty). This corresponds to one less death from prostate cancer per 1000 men screened over 10 years. Direct comparative data on biopsy and treatment related complications from the included trials were limited. Using modelling, we estimated that for every 1000 men screened, approximately 1, 3, and 25 more men would be hospitalised for sepsis, require pads for urinary incontinence, and report erectile dysfunction, respectively. CONCLUSIONS: At best, screening for prostate cancer leads to a small reduction in disease-specific mortality over 10 years but has does not affect overall mortality. Clinicians and patients considering PSA based screening need to weigh these benefits against the potential short and long term harms of screening, including complications from biopsies and subsequent treatment, as well as the risk of overdiagnosis and overtreatment. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration number CRD42016042347.
引用
- Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018. PMID: 30185521. doi:10.1136/bmj.k3519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。